Abbott Laboratories

• UnitedHealth exceeded Wall Street expectations with strong third-quarter revenue and earnings. • The medical care ratio improved due to effective cost control and pricing discipline. • Management raised full-year adjusted earnings guidance following robust segment-level momentum.

• Abbott secured FDA approval for its CardioMEMS heart failure system features. • The company reported annual revenue of $44.33B with net profit of $6.52B. • Analysts issued Buy ratings with an average price target of $121.29.

• Danaher reaffirmed its third-quarter and full-year financial guidance. • Julie Sawyer Montgomery will assume the CEO role on October 1. • Danaher reports annual revenue of $24.57B and net profit of $3.61B.

• Intuitive Surgical exceeded quarterly expectations, raising full-year guidance on high global procedure volumes. • Strong Da Vinci 5 platform adoption and recurring revenue streams drove institutional investor confidence. • Technical indicators show a sell signal, despite positive fundamental growth and market positioning.

• Stryker stock fell due to concerns regarding orthopedic demand and hospital capital spending. • Elevated treasury yields are compressing valuation multiples for high-growth medical technology firms. • Technical breaches of support levels and institutional profit-taking contributed to intraday price volatility.

• Intuitive Surgical shares declined after missing second-quarter revenue and procedure volume expectations. • Management lowered 2026 procedure growth guidance due to slowing international elective surgery rates. • Increased R&D spending and rising costs compressed operating margins, triggering institutional selling.